Palisade Bio, Inc.: 5%+ holders

As of November 10, 2026, 9 holders' latest Schedule 13D or 13G filings report owning 5% or more of Palisade Bio, Inc. The largest reported stake is Janus Henderson Group Plc's, at 9.99%. 26 filings are on record since August 14, 2025 (Schedule 13G, December 8, 2025).

Octagon Capital Advisors LP also filed stake reports on 8 other companies ↓

Sell to companies like Palisade Bio, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Filing 2026-11-09 · Reporting person: Soleus Capital Master Fund, L.P. · Sole voting: 0 · Shared voting: 14,996,154 · Sole dispositive: 0 · Shared dispositive: 14,996,154 · SCHEDULE 13G/A, 2026-11-09
• Filing 2026-10-30 · Reporting person: Vanguard Capital Management · Sole voting: 1,107,785 · Shared voting: 0 · Sole dispositive: 8,995,805 · Shared dispositive: 0 · SCHEDULE 13G, 2026-10-30
• Filing 2026-08-14 · Reporting person: Commodore Capital LP · Sole voting: 0 · Shared voting: 0 · Sole dispositive: 0 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-14
• Filed 2026-08-13 · Holder: Soleus Capital Master Fund, L.P. · Percent: 7.5% · SCHEDULE 13G/A
• Filing 2026-07-29 · Reporting person: BlackRock, Inc. · Sole voting: 10,326,107 · Shared voting: 0 · Sole dispositive: 10,436,760 · Shared dispositive: 0 · SCHEDULE 13G, 2026-07-29

Palisade Bio, Inc. has 26 Schedule 13D or 13G filings on record since 2025-08-14. 9 holders' latest filing reports 5% or more of common stock, $0.01 par value per share. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind Palisade Bio, Inc. and the warning signs.

See Palisade Bio, Inc.'s free Snapshot Watch Palisade Bio, Inc.: email me the next time it files something

Free to see. No signup.

Keep reading

More on Palisade Bio, Inc. and the records around it.

Palisade Bio, Inc. elsewhere on the record

• Who owns it

Companies that share a holder

• Octagon Capital Advisors LP also filed stake reports on 8 other companies: Precision BioSciences, Inc. (Nov 2026), Context Therapeutics Inc. (Jul 2026), Corbus Pharmaceuticals Holdings, Inc. (May 2026)
• Squadron Master Fund LP also filed stake reports on 14 other companies: Contineum Therapeutics, Inc. (Oct 2026), TCGX Acquisition Corp. II (Oct 2026), C4 Therapeutics, Inc. (Aug 2026)
• Soleus Capital Master Fund, L.P. also filed stake reports on 24 other companies: Beta Bionics, Inc. (Nov 2026), Evolus, Inc (Nov 2026), INSPIRE MEDICAL SYSTEMS, INC. (Nov 2026)

Want the whole picture on Palisade Bio, Inc.?

Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC

A Full Report on Palisade Bio, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Palisade Bio, Inc. covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   26 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Voting and dispositive power, as filed

Swipe the table sideways to see every column.

The latest filing identifies Palisade Bio, Inc. by CUSIP 696389402 and gives its principal executive office as 4600 South Syracuse Street, Suite 900, Denver, CO 80237 (SCHEDULE 13G/A, 2026-11-09).

Timeline

Swipe the table sideways to see every column.

Questions about who owns Palisade Bio, Inc.

Who owns Palisade Bio, Inc.?

On this page, 9 holders' latest ownership filings report 5% or more of Palisade Bio, Inc.: Janus Henderson Group Plc (9.99%, Schedule 13G, filed 2025-12-08), RA Capital Management, L.P. (9.9%, Schedule 13G/A, filed 2026-05-15), Soleus Capital Master Fund, L.P. (8.6%, Schedule 13G/A, filed 2026-11-09), Perceptive Advisors LLC (7.9%, Schedule 13G/A, filed 2026-05-15) and Octagon Capital Advisors LP (6.4%, Schedule 13G, filed 2026-02-10); 4 more are listed above.

Who are the largest shareholders of Palisade Bio, Inc.?

By the share each holder's latest filing reports, the largest holders of Palisade Bio, Inc. on this page are Janus Henderson Group Plc (9.99%), RA Capital Management, L.P. (9.9%) and Soleus Capital Master Fund, L.P. (8.6%).

When did Janus Henderson Group Plc buy into Palisade Bio, Inc.?

The filings give report dates, not purchase dates. The earliest filing from Janus Henderson Group Plc on this page is the Schedule 13G, filed 2025-12-08, reporting 9.99%.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 26 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Tools for this story

Each opens in a new tab, filled in for Palisade Bio, Inc.. With no account yet, you sign up free and land on the result.

• Get an alert when Palisade Bio, Inc. is mentioned again
• Find former Palisade Bio, Inc. employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes